CoChat

Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer

Open access
Rivera, Edgardo, Cianfrocca, Mary · 2015 · Cancer Chemotherapy and Pharmacology

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Abstract

Taxanes are an established option in the standard treatment paradigm for patients with metastatic breast cancer (MBC). Neuropathy is a common, dose-limiting side effect of taxane therapy that is often managed by dose reductions and delays. The severity, time to onset, and improvement in neuropathy are important considerations for patient management and vary among currently approved taxanes. The rate of grade ≥3 neuropathy with taxanes has been shown to be dose and schedule dependent; however, time to improvement to grade ≤1 is typically shorter for nab-paclitaxel than for other taxanes in patients with MBC. Many tools for assessing patient-reported neuropathy exist. Because MBC is incurable and patient quality of life must be critically considered when making treatment decisions, there is a need for more prospective trials to assess patient-reported neuropathy. Validated predictors of taxane-related neuropathy may play an important role in treatment decisions in the future. This review will focus on the toxicity profile (i.e., neuropathy) of each of the taxanes used in the treatment of MBC, will provide updates on tools used for the assessment of neuropathy, and will highlight newly discovered predictors of taxane-related neuropathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00280-014-2607-5

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Research works printed but not linked: 1

  1. Hirsh V, Owen SP, Ko A, Renschler MF, Socinski MA (2013) nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC). In: 15th World conference on lung cancer, poster P1 10-044

Cited by

See all 159

Metadata

Authors
Rivera, E., & Cianfrocca, M.
Affiliations
Banner MD Anderson Cancer Center (US)
Corresponding author
Rivera, Edgardo
Venue
Cancer Chemotherapy and Pharmacology
Published
2015-01-18
Volume
75
Issue
4
Pages
659-670
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2061239263
Cited by
159
References
89
Citations by year
2026: 6 · 2025: 16 · 2024: 11 · 2023: 14 · 2022: 19 · 2021: 15 · 2020: 19 · 2019: 7 · 2018: 14 · 2017: 16 · 2016: 14 · 2015: 8
FWCI
1.86
Type
journal article
Language
en
Open access
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Celgene
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
taxanes, neuropathy, metastatic breast cancer, nab-paclitaxel, paclitaxel, docetaxel, chemotherapy toxicity, dose-limiting toxicity, patient-reported outcomes, quality of life
MeSH terms
Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Neoplasm Metastasis, Neuralgia, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. https://app.cochat.ai/papers/10.1007/s00280-014-2607-5
The paper
Rivera, E., & Cianfrocca, M. (2015). Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-014-2607-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.